Showing results (51-60 of 58) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 58 results.
Eclinicalmedicine|July 3, 2023
Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trialElena Zamagni, Stefania Oliva, Francesca Gay, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 5, 2015
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working GroupAntonio Palumbo, Hervé Avet-Loiseau, Stefania Oliva, et al.
Nutrients|September 13, 2025
Investigating Neophobia Towards New Food Technologies in Italy: The CoNF&TTI Cross-Sectional StudyCarmela Protano, Federica Valeriani, Patrizia Calella, et al.
Annali Di Igiene : Medicina Preventiva E Di Comunita|October 7, 2024
Sleep quality among Italian university students: the UnSleep multicenter studyFrancesca Gallè, Fabiano Grassi, Federica Valeriani, et al.
Nutrients|March 13, 2025
Changing Food in a Changing World: Assessing Compliance to Insects, Cultivated Meat, and Soil-Less Products Among Italian UndergraduatesFrancesca Gallè, Federica Valeriani, Jole Del Prete, et al.
Cancer Medicine|March 17, 2026
Next Generation Flow and Next Generation Sequencing for Measurable Residual Disease Assessment in Multiple Myeloma Patients: A Real-Life Italian Multicenter Harmonization ExperienceStefania Oliva, Marina Martello, Elona Saraci, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2021
Consolidation and Maintenance in Newly Diagnosed Multiple MyelomaPieter Sonneveld, Meletios A Dimopoulos, Meral Beksac, et al.
The Lancet. Haematology|May 4, 2020
Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 studyMichele Cavo, Francesca Gay, Meral Beksac, et al.
Pageof 6